SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

J Clin Oncol. 2017;35(26):3065-3074.

Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.

, , , , , , , , , , , , , , , , , , , , , ,

제1저자 이준구 · 교신저자 김태민, 주영석

PMID 28498782 DOI 10.1200/JCO.2016.71.9096 IF 44.7 혈액종양내과
소속 (1)
  1. June-Koo Lee, Jeonghwan Youk, Seongyeol Park, Yohan An, Joon Kim, Young Seok Ju, Korea Advanced Institute of Science and Technology; Junehawk Lee, Korea Institute of Science and Technology Information, Daejeon; Sehui Kim, Bhumsuk Keam, Dong-Wan Kim, Dae Seog Heo, Young Tae Kim, Yoon Kyung Jeon, Doo Hyun Chung, Tae Min Kim, Seoul National University Hospital; Soyeon Kim, Bhumsuk Keam, Dong-Wan Kim, Dae Seog Heo, Young Tae Kim, Ja-Lok Ku, Yoon Kyung Jeon, Tae Min Kim, Seoul National University Cancer Research Institute; Jin-Soo Kim, Seoul Metropolitan Government-Seoul National University Boramae Medical Center; Se-Hoon Lee, Keunchil Park, Sungkyunkwan University School of Medicine; Doo Hyun Chung, Seoul National University College of Medicine, Seoul; Se Hyun Kim, Jong Seok Lee, Seoul National University Bundang Hospital, Seongnam, Republic of Korea; and Peter J. Park, Harvard Medical School, Boston, MA.

Abstract

Purpose Histologic transformation of EGFR mutant lung adenocarcinoma (LADC) into small-cell lung cancer (SCLC) has been described as one of the major resistant mechanisms for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). However, the molecular pathogenesis is still unclear. Methods We investigated 21 patients with advanced EGFR-mutant LADCs that were transformed into EGFR TKI-resistant SCLCs. Among them, whole genome sequencing was applied for nine tumors acquired at various time points from four patients to reconstruct their clonal evolutionary history and to detect genetic predictors for small-cell transformation. The findings were validated by immunohistochemistry in 210 lung cancer tissues. Results We identified that EGFR TKI-resistant LADCs and SCLCs share a common clonal origin and undergo branched evolutionary trajectories. The clonal divergence of SCLC ancestors from the LADC cells occurred before the first EGFR TKI treatments, and the complete inactivation of both RB1 and TP53 were observed from the early LADC stages in sequenced tumors. We extended the findings by immunohistochemistry in the early-stage LADC tissues of 75 patients treated with EGFR TKIs; inactivation of both Rb and p53 was strikingly more frequent in the small-cell-transformed group than in the nontransformed group (82% v 3%; odds ratio, 131; 95% CI, 19.9 to 859). Among patients registered in a predefined cohort (n = 65), an EGFR mutant LADC that harbored completely inactivated Rb and p53 had a 43× greater risk of small-cell transformation (relative risk, 42.8; 95% CI, 5.88 to 311). Branch-specific mutational signature analysis revealed that apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC)-induced hypermutation was frequent in the branches toward small-cell transformation. Conclusion EGFR TKI-resistant SCLCs are branched out early from the LADC clones that harbor completely inactivated RB1 and TP53. The evaluation of RB1 and TP53 status in EGFR TKI-treated LADCs is informative in predicting small-cell transformation.

Comment · 정정

그 밖의 정보
출판 형태
Journal Article
저널
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · eISSN 1527-7755
전자 출판
2017-05-12
MeSH
Adenocarcinoma / drug therapy / enzymology / genetics / pathology · Adenocarcinoma of Lung · Adult · Carcinoma, Small Cell / drug therapy / enzymology / genetics / pathology · Cell Transformation, Neoplastic / genetics / pathology · Drug Resistance, Neoplasm · ErbB Receptors / antagonists & inhibitors / genetics · Female · Humans · Lung Neoplasms / drug therapy / enzymology / genetics / pathology · Male · Middle Aged · Protein Kinase Inhibitors / pharmacology
Substances
Protein Kinase Inhibitors · EGFR protein, human · ErbB Receptors